O. Grobe

发表

Diagnostic accuracy of six commercial SARS-CoV-2 IgG/total antibody assays and identification of SARS-CoV-2 neutralizing antibodies in convalescent sera

H. Fickenscher, R. Rose, A. Strömer, 2020, medRxiv.

Humoral immune response after different SARS-CoV-2 vaccination regimens

H. Fickenscher, R. Rose, O. Grobe, 2022, BMC Medicine.

The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines

H. Fickenscher, R. Rose, O. Grobe, 2021 .

Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads to humoral immune response against SARS-CoV-2, which is comparable to that according to a homologous mRNA vaccination scheme

H. Fickenscher, R. Rose, O. Grobe, 2021, medRxiv.

Expression of the NF-κB target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells

A. Arlt, U. Fölsch, M. Kruse, 2001, Oncogene.

Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection

H. Fickenscher, R. Rose, O. Grobe, 2020, Microorganisms.

Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells.

A. Arlt, U. Fölsch, H. Schäfer, 2001, Oncogene.

Delta or Omicron BA.1/2‐neutralizing antibody levels and T‐cell reactivity after triple‐vaccination or infection

H. Fickenscher, R. Rose, Miriam Schäfer, 2022, Allergy.

Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination

H. Fickenscher, R. Rose, O. Grobe, 2021, Vaccines.